TarMart Solution Ecosystem & Related Targets
Complete reagent toolkit for DAO drug discovery and D-serine pathway modulation. Precision tools for metabolic enzyme drug discovery:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DAO Recombinant Protein (Full-length, WT & Mutant Panel). High purity (>95%), FAD-bound active form. Sequence Verified. HEK293 Expressed. | View DAO Products |
| Gene Delivery | DAO Lentivirus / Promise-ORF. Full-length ORF for stable cell lines. Endotoxin <1EU/ug. | View DAO Products |
| Benchmark Ab | Anti-DAO Recombinant Antibody. Sequence-defined positive control for Western, IHC, and occupancy assays. | View DAO Products |
| Validator | DAO siRNA Set. For knockdown verification and specificity controls in cellular D-serine assays. | View DAO Products |
| Related Target 1 | DDO (D-aspartate Oxidase). Paralog flavoenzyme for cross-selectivity counter-screening. | View DDO Products |
| Related Target 2 | SRR (Serine Racemase). D-serine synthesis enzyme for pathway studies. | View SRR Products |
| Related Target 3 | GRIN1 (NMDA Receptor NR1) ECD Protein. Glycine-binding subunit, D-serine target validation. | View GRIN1 Products |
| Related Target 4 | GRIN2B (NMDA Receptor NR2B) ECD Protein. Modulatory subunit for cognitive function assays. | View GRIN2B Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity Inhibition (FAD-dependent) | High-specific-activity DAO protein (>95% purity, theoretical MW verified) suitable for H2O2 detection or D-serine consumption assays. Expression systems optimized for native folding and FAD binding. |
| Pathway Selectivity (vs. DDO, MAO) | Strict sequence homology verified by mass spec; available DDO homolog for counter-screening. Off-target panels with >95% purity. |
| Cellular D-serine Elevation | DAO Lentivirus for stable cell line construction; quantifiable D-serine modulation in vitro. |
| Lack of Controls | Clinical Benchmark Antibodies included for reliable standard curves. |
| False Positives / Specificity | Validated siRNA included for target-specific inhibition confirmation in cellular environments. |
Live DAO R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DAO (D-amino acid oxidase) therapeutics is intensifying, with major players focusing on small molecule inhibitors to treat schizophrenia and cognitive impairment. By preventing the degradation of D-serine, DAO inhibitors enhance NMDA receptor function, addressing the unmet need in schizophrenia negative symptoms and cognitive impairment—domains poorly served by existing dopaminergic antipsychotics. Recent preclinical and early-phase efforts indicate a shift toward CNS-penetrant small molecules and adjuvant therapy combinations with standard antipsychotics. The next wave of R&D is targeting Alzheimer's disease (amyloid clearance modulation) and ALS (excitotoxicity regulation), positioning DAO as a cross-indication metabolic target. Key players include Takeda (Luvadaxistat), SyneuRx, and emerging biotechs.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Benzoate derivatives, Triazole analogs | Schizophrenia (Negative/Cognitive), Alzheimer's | Enzyme Kinetic Assay (Need FAD-bound active DAO protein with validated specific activity) |
| Gene Therapy | Emerging Biotechs | Neuropathic Pain | In vitro validation (Need accurate Lentivirus constructs) |
| D-Amino Acid Analogs | D-Cycloserine variants | PTSD, Depression | Receptor Binding Competition (Need pure NMDA receptor ECD proteins) |
| Pathway Modulators | SRR Activators + DAO Inhibitors | Cognitive Enhancement | D-Serine Quantification Panel (Need both DAO and SRR enzymes for metabolic flux assays) |
Key Mutations in DAO (from ALS Patients)
Three clinically relevant mutations in the DAO gene have been identified in patients with ALS (Amyotrophic Lateral Sclerosis). These mutations impair FAD binding and significantly reduce or abolish enzymatic activity:
- Gln201Arg (found in an ALS patient): Impairs FAD binding; 20-fold decreased affinity for cofactor. Evidence: UniProt P14920 VAR_089068.
- Arg38His (found in an ALS patient): Abolishes activity; impairs FAD binding; over 900-fold decreased affinity. Evidence: UniProt P14920 VAR_089069.
- Cys310Ser (found in an ALS patient): Impairs FAD binding; over 200-fold decreased affinity. Evidence: UniProt P14920 VAR_089070.
Understanding these loss-of-function mutations is critical for developing inhibitors that restore or bypass impaired DAO activity in disease contexts, and for validating assay specificity using mutant protein panels.